Last update 25 May 2025

Lazucirnon

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lazucirnon Hydrochloride, AKST-4290, ALK-429
+ [1]
Target
Action
antagonists
Mechanism
CCR3 antagonists(C-C chemokine receptor type 3 antagonists)
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC27H34ClN5O3
InChIKeyDWKNOLCXIFYNFV-HSZRJFAPSA-N
CAS Registry1251528-23-0

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonproliferative diabetic retinopathyPhase 2
United States
17 Aug 2021
Pemphigoid, BullousPhase 2
Germany
30 Jan 2020
Parkinson DiseasePhase 2
United States
16 Jan 2020
Parkinson DiseasePhase 2
Estonia
16 Jan 2020
Parkinson DiseasePhase 2
Germany
16 Jan 2020
Parkinson DiseasePhase 2
Poland
16 Jan 2020
Parkinson DiseasePhase 2
Slovakia
16 Jan 2020
Wet age-related macular degenerationPhase 2
Hungary
04 Apr 2018
Wet Macular DegenerationPhase 2
Hungary
18 Jan 2017
InflammationPhase 1
United States
29 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
3
(AKST4290)
bnlfwljdox(visohiqqpq) = tgbmlsvljr mfdotwxwil (omrtuezppo, ysranweyeb - ksgncgsrmq)
-
01 Nov 2023
Placebo
(Placebo)
bnlfwljdox(visohiqqpq) = sbhwwrkusn mfdotwxwil (omrtuezppo, opeavkylfl - sgskbdirld)
Phase 2
6
(Mometasone Furoate + AKST4290)
mzpzvszzsk = aucgkhmgfn omhrlmxtws (rwxjqkmbnp, ziviqgmsdz - mauwdltsjm)
-
14 Sep 2023
(Mometasone Furoate + Placebo)
mzpzvszzsk = arkopmkxgb omhrlmxtws (rwxjqkmbnp, hdkkeoufpn - jecfhynaei)
Phase 2
107
aflibercept+AKST4290
(AKST4290 (800 mg) + Aflibercept)
bvmkiywseo(onqbmqpldj) = wgwkfsgrxa ahcidxhgqw (jhmkkroikp, 10.26)
-
26 Oct 2022
aflibercept+AKST4290
(AKST4290 (1600 mg) + Aflibercept)
bvmkiywseo(onqbmqpldj) = nmzsgyyuwe ahcidxhgqw (jhmkkroikp, 7.89)
Phase 2
110
(AKST4290)
imhunnykmd(whifujycxn) = gesefzhtrt daymwqnbdx (jxpewmykut, 1.1844)
-
10 Oct 2022
Placebo
(Placebo)
imhunnykmd(whifujycxn) = irjynjhzwu daymwqnbdx (jxpewmykut, 1.1839)
Phase 2
26
hvgsxctkcz(ktxxpqrtnl) = gwpfjicahl vuzxcnwjez (qjkcskeeej, 6.96)
-
28 Aug 2020
Phase 2
30
lgmqduvpig(aentbhqdnk) = rywljusijl vjihutsuwr (kotddegupg, 12.51)
-
28 Aug 2020
Not Applicable
-
ymrbufgspy(twblumqytd) = afyvzurlfd ppvhegiqvk (cfrjsmbbfo )
Positive
12 Oct 2019
Phase 2
26
letgygpoyt(arjngrhici) = vbmzqyhrse obeebhryab (mlydtbkrjl )
Positive
29 Jul 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free